Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000409231 | SCV000487088 | pathogenic | Glycogen storage disease, type IV | 2016-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000706367 | SCV000835411 | pathogenic | Glycogen storage disease, type IV; Glycogen storage disease IV, classic hepatic | 2023-12-01 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gly97Glufs*46) in the GBE1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GBE1 are known to be pathogenic (PMID: 15452297, 20058079). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with glycogen storage disease (PMID: 12913206, 21917543). ClinVar contains an entry for this variant (Variation ID: 371491). For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV003137987 | SCV003818102 | pathogenic | not provided | 2022-09-12 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000409231 | SCV004198737 | pathogenic | Glycogen storage disease, type IV | 2022-10-06 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005027465 | SCV005657844 | pathogenic | Adult polyglucosan body disease; Glycogen storage disease, type IV | 2024-01-27 | criteria provided, single submitter | clinical testing |